Please assess the completion status of the following clinical trial:

Trial Title: Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Any patient with a high-risk hematologic or oncologic diagnosis in which allogeneic HSCT is thought to be beneficial, and in whom front-line therapy has already been applied. High risk is defined as:~   * Acute leukemia in 3rd or greater CR or with persistent disease~  * Myelodysplastic syndrome (MDS) other than RA or RARS subtypes.~  * Hodgkin's or Non-Hodgkin's lymphoma in 3rd or greater remission or with persistent disease.~  * Myeloma in 3rd or greater remission or with less than PR to most recent therapy.~  * Chronic myelogenous (or myeloid) leukemia (CML) resistant to STI therapy~2. Patients must have a related donor who is at least a 4 antigen match at the HLA-A; B; C; DR loci.~3. Patients must adequate organ function:~   * LVEF of \> or = 50%~  * DLCO \> or = 50% of predicted corrected for hemoglobin~  * Adequate liver function as defined by a serum bilirubin \< or = 1.8, AST or ALT \< or = 2.5X upper limit of normal~  * GFR of \> or = 60 mL/min/1.73m2~4. Performance status \> or = 80% (TJU Karnofsky) for patients \> or = 60 years old or \> or = 70% for patients \< 60.~5. HCT-CI Score \< or = 4 points for patients \> or = 60 years old or \< or = 5 points for patients \< 60.~6. Patients must be willing to use contraception if they have childbearing potential~7. Able to give informed consent~Exclusion Criteria:~1. Performance status \< 80% (TJU Karnofsky) for patients \> or = 60 years old or \< 70% for patients \< 60.~2. HCT-CI Score \> 4 points for patients \> or = 60 years old or \> 5 points for patients \< 60.~3. HIV positive~4. Active involvement of the central nervous system with malignancy~5. Inability to obtain informed consent~6. Pregnancy~7. Patients with life expectancy of \< 6 months for reasons other than their underlying hematologic/oncologic disorder~8. Patients who have received alemtuzumab within 8 weeks of the transplant admission, or who have recently received horse or rabbit ant-thymocyte globulin and have an ATG level of \> or = 2 ugm/ml~9. Patients with evidence of another malignancy, exclusive of a skin cancer that requires only local treatment, should not be enrolled on this protocol~Donor Selection All donors are selected and screened for their ability to provide adequate infection-free apheresis products for the patient in a manner that does not put the donor at risk for negative consequences. Donor selection will be in compliance with 21 CFR 1271 and TJU BMT Program SOP CP: P009.03.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transplant Treatment Group (Type: EXPERIMENTAL): All patients treated on this research study.

Based on this trial design, predict the completion outcome and termination type (if applicable).